查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1556568

肿瘤微环境市场报告：2030 年趋势、预测与竞争分析

Tumor Microenvironment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

肿瘤微环境趋势与预测

预计2024年至2030年全球肿瘤微环境市场将以11.2%的复合年增长率成长。该市场的主要驱动力是癌症发病率上升、肿瘤微环境在免疫肿瘤学中的重要性日益增加以及政府和製药公司对肿瘤学研究的投资增加。全球肿瘤微环境市场前景广阔，生物製药公司、医院、诊断实验室、研究机构和CRO市场充满机会。

按部位分類的肿瘤微环境

这项研究提供了按癌症类型、产品、治疗方法、最终用途和区域分類的全球肿瘤微环境的预测。

肿瘤微环境市场洞察

Lucintel 预测，在预测期内，肺癌仍将是最大的细分市场。

生物製药公司仍然是市场上最大的部分。

由于尖端技术的采用增加、政府对生命科学研究的资助以及大型製药企业的存在，北美可能仍将是最大的地区。

常问问题

Q1.市场成长预测是多少：

A1. 2024年至2030年，全球肿瘤微环境市场预计将以11.2%的复合年增长率成长。

Q2. 影响市场成长的关键驱动因素是：

A2. 这个市场的主要驱动力是癌症盛行率的上升、肿瘤微环境在免疫肿瘤学中日益重要，以及政府和製药公司对肿瘤学研究的投资不断增加。

Q3.市场的主要细分市场是：

A3. 全球肿瘤微环境市场前景广阔，生物製药公司、医院、诊断实验室、研究机构和CRO市场充满机会。

Q4.市场的主要企业是：

A4.主要肿瘤微环境公司如下：

  • Thermo Fisher Scientific
  • Illumina
  • Danaher
  • Merck
  • BD Biosciences
  • Promega
  • Bio-Techne
  • Bio-Rad Laboratories
  • Hoffmann-La Roche
  • QIAGEN

Q5.未来最大的细分市场是什么？

A5.Lucintel 预计肺癌在预测期内仍将是其最大的细分市场。

Q6.未来五年预计哪些地区的市场成长最大？

A6. 由于尖端技术的采用增加、政府对生命科学研究的资助以及大型製药企业的存在，预计北美仍将是最大的地区。

Q7. 可以客製化报告吗？

A7。

目录

第一章执行摘要

第二章全球肿瘤微环境市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球肿瘤微环境市场趋势（2018-2023）与预测（2024-2030）
  • 按癌症类型分類的全球肿瘤微环境市场
    • 肺癌
    • 大肠直肠癌
    • 乳癌
    • 摄护腺癌
    • 膀胱癌
    • 其他的
  • 按产品分類的肿瘤微环境市场
    • T细胞
    • 肿瘤相关巨噬细胞
    • 骨髓源性抑制细胞
    • 癌症相关纤维母细胞
    • 调节性T细胞
    • 其他的
  • 按治疗方法的肿瘤微环境市场
    • 单株抗体
    • 细胞激素
    • 癌症疫苗
    • 溶瘤病毒
    • 过继性细胞疗法
    • 其他的
  • 按最终用途分類的全球肿瘤微环境市场
    • 生物製药公司
    • 医院
    • 诊断实验室
    • 调查机构
    • CRO（药物委外研发机构）
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球肿瘤微环境市场：按地区
  • 北美肿瘤微环境市场
  • 欧洲肿瘤微环境市场
  • 亚太肿瘤微环境市场
  • 其他地区肿瘤微环境市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按癌症类型分類的全球肿瘤微环境市场成长机会
    • 按产品分類的全球肿瘤微环境市场成长机会
    • 按治疗方法方式分類的全球肿瘤微环境市场成长机会
    • 全球肿瘤微环境市场成长机会（依最终用途）
    • 按地区分類的全球肿瘤微环境市场成长机会
  • 全球肿瘤微环境市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 全球肿瘤微环境市场的产能扩张
    • 全球肿瘤微环境市场的併购与合资
    • 认证和许可

第七章主要企业概况

  • Thermo Fisher Scientific
  • Illumina
  • Danaher
  • Merck
  • BD Biosciences
  • Promega
  • Bio-Techne
  • Bio-Rad Laboratories
  • Hoffmann-La Roche
  • QIAGEN
简介目录

Tumor Microenvironment Trends and Forecast

The future of the global tumor microenvironment market looks promising with opportunities in the biopharmaceutical company, hospital, diagnostic laboratory, research institute, and contract research organization markets. The global tumor microenvironment market is expected to grow with a CAGR of 11.2% from 2024 to 2030. The major drivers for this market are rising prevalence of cancer, emerging importance of the tumor microenvironment in immuno-oncology, along with the governments and pharmaceutical corporations boosting their investments in oncology research.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Tumor Microenvironment by Segment

The study includes a forecast for the global tumor microenvironment by cancer type, product, therapy, end use, and region.

Tumor Microenvironment Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Bladder Cancer
  • Others

Tumor Microenvironment Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • T Cells
  • Tumor-Associated Macrophages
  • Myeloid-Derived Suppressor Cells
  • Cancer-Associated Fibroblasts
  • Regulatory T Cells
  • Others

Tumor Microenvironment Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • Monoclonal Antibodies
  • Cytokines
  • Cancer Vaccines
  • Oncolytic Viruses
  • Adoptive Cell Therapies
  • Others

Tumor Microenvironment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Biopharmaceutical Companies
  • Hospital
  • Diagnostic Laboratories
  • Research Institutes
  • Contract Research Organizations
  • Others

Tumor Microenvironment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Tumor Microenvironment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies tumor microenvironment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the tumor microenvironment companies profiled in this report include-

  • Thermo Fisher Scientific
  • Illumina
  • Danaher
  • Merck
  • BD Biosciences
  • Promega
  • Bio-Techne
  • Bio-Rad Laboratories
  • Hoffmann-La Roche
  • QIAGEN

Tumor Microenvironment Market Insights

Lucintel forecasts that lung cancer will remain the largest segment over the forecast period.

Within this market, biopharmaceutical company will remain the largest segment.

North America will remain the largest region over the forecast period due to high adoption of modern technology, funding from the government for life science research, and the presence of big pharmaceutical and biotech corporations in the region.

Features of the Global Tumor Microenvironment Market

Market Size Estimates: Tumor microenvironment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Tumor microenvironment market size by cancer type, product, therapy, end use, and region in terms of value ($B).

Regional Analysis: Tumor microenvironment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer type, product, therapy, end use, and regions for the tumor microenvironment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the tumor microenvironment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for tumor microenvironment market?

Answer: The global tumor microenvironment market is expected to grow with a CAGR of 11.2% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the tumor microenvironment market?

Answer: The major drivers for this market are rising prevalence of cancer, emerging importance of the tumor microenvironment in immuno-oncology, along with the governments and pharmaceutical corporations boosting their investments in oncology research.

Q3. What are the major segments for tumor microenvironment market?

Answer: The future of the global tumor microenvironment market looks promising with opportunities in the biopharmaceutical company, hospital, diagnostic laboratory, research institute, and contract research organization markets.

Q4. Who are the key tumor microenvironment market companies?

Answer: Some of the key tumor microenvironment companies are as follows:

  • Thermo Fisher Scientific
  • Illumina
  • Danaher
  • Merck
  • BD Biosciences
  • Promega
  • Bio-Techne
  • Bio-Rad Laboratories
  • Hoffmann-La Roche
  • QIAGEN

Q5. Which tumor microenvironment market segment will be the largest in future?

Answer: Lucintel forecasts that lung cancer will remain the largest segment over the forecast period.

Q6. In tumor microenvironment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high adoption of modern technology, funding from the government for life science research, and the presence of big pharmaceutical and biotech corporations in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the tumor microenvironment market by cancer type (lung cancer, colorectal cancer, breast cancer, prostate cancer, bladder cancer, and others), product (T cells, tumor-associated macrophages, myeloid-derived suppressor cells, cancer-associated fibroblasts, regulatory t cells, and others), therapy (monoclonal antibodies, cytokines, cancer vaccines, oncolytic viruses, adoptive cell therapies, and others), end use (biopharmaceutical companies, hospital, diagnostic laboratories, research institutes, contract research organizations, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Tumor Microenvironment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Tumor Microenvironment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Tumor Microenvironment Market by Cancer Type
    • 3.3.1: Lung Cancer
    • 3.3.2: Colorectal Cancer
    • 3.3.3: Breast Cancer
    • 3.3.4: Prostate Cancer
    • 3.3.5: Bladder Cancer
    • 3.3.6: Others
  • 3.4: Global Tumor Microenvironment Market by Product
    • 3.4.1: T Cells
    • 3.4.2: Tumor-Associated Macrophages
    • 3.4.3: Myeloid-Derived Suppressor Cells
    • 3.4.4: Cancer-Associated Fibroblasts
    • 3.4.5: Regulatory T Cells
    • 3.4.6: Others
  • 3.5: Global Tumor Microenvironment Market by Therapy
    • 3.5.1: Monoclonal Antibodies
    • 3.5.2: Cytokines
    • 3.5.3: Cancer Vaccines
    • 3.5.4: Oncolytic Viruses
    • 3.5.5: Adoptive Cell Therapies
    • 3.5.6: Others
  • 3.6: Global Tumor Microenvironment Market by End Use
    • 3.6.1: Biopharmaceutical Companies
    • 3.6.2: Hospital
    • 3.6.3: Diagnostic Laboratories
    • 3.6.4: Research Institutes
    • 3.6.5: Contract Research Organizations
    • 3.6.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Tumor Microenvironment Market by Region
  • 4.2: North American Tumor Microenvironment Market
    • 4.2.1: North American Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
    • 4.2.2: North American Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others
  • 4.3: European Tumor Microenvironment Market
    • 4.3.1: European Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
    • 4.3.2: European Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others
  • 4.4: APAC Tumor Microenvironment Market
    • 4.4.1: APAC Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
    • 4.4.2: APAC Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others
  • 4.5: ROW Tumor Microenvironment Market
    • 4.5.1: ROW Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
    • 4.5.2: ROW Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Tumor Microenvironment Market by Cancer Type
    • 6.1.2: Growth Opportunities for the Global Tumor Microenvironment Market by Product
    • 6.1.3: Growth Opportunities for the Global Tumor Microenvironment Market by Therapy
    • 6.1.4: Growth Opportunities for the Global Tumor Microenvironment Market by End Use
    • 6.1.5: Growth Opportunities for the Global Tumor Microenvironment Market by Region
  • 6.2: Emerging Trends in the Global Tumor Microenvironment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Tumor Microenvironment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Tumor Microenvironment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Thermo Fisher Scientific
  • 7.2: Illumina
  • 7.3: Danaher
  • 7.4: Merck
  • 7.5: BD Biosciences
  • 7.6: Promega
  • 7.7: Bio-Techne
  • 7.8: Bio-Rad Laboratories
  • 7.9: Hoffmann-La Roche
  • 7.10: QIAGEN